https://www.selleckchem.com/products/BIBF1120.html
ophrenia. FUNDING ACKNOWLEDGEMENTS Supported by funding from Intra-Cellular Therapies, Inc.STUDY OBJECTIVES Depression is the leading cause of disability worldwide, with fewer than 50% of treated patients achieving full remission. This study ("CLARITY," ACP-103-042 NCT0301834 examined the 5-HT2A inverse agonist pimavanserin (PIM) as a potential adjunctive treatment for major depressive disorder (MDD). METHOD Adult female and male subjects with a DSM-5 primary diagnosis of a major depressive episode as part of MDD, inadequate response
Like
Comment
Share
